145 related articles for article (PubMed ID: 21631271)
21. The mTOR downstream regulator (p-4EBP1) is a novel independent prognostic marker in ovarian cancer.
Alabdullah ML; Ahmad DA; Moseley P; Madhusudan S; Chan S; Rakha E
J Obstet Gynaecol; 2019 May; 39(4):522-528. PubMed ID: 30712414
[TBL] [Abstract][Full Text] [Related]
22. Activation of the Akt/mammalian target of rapamycin pathway in combined hepatocellular carcinoma and cholangiocarcinoma: significant correlation between p-4E-BP1 expression in cholangiocarcinoma component and prognosis.
Okumura Y; Kohashi K; Tanaka Y; Kato M; Maehara Y; Ogawa Y; Oda Y
Virchows Arch; 2020 Jun; 476(6):881-890. PubMed ID: 31927624
[TBL] [Abstract][Full Text] [Related]
23. Mammalian target of rapamycin pathway activity in alveolar soft part sarcoma.
Reis H; Hager T; Wohlschlaeger J; Bauer S; Katenkamp K; Katenkamp D; Baba HA
Hum Pathol; 2013 Oct; 44(10):2266-74. PubMed ID: 23871289
[TBL] [Abstract][Full Text] [Related]
24. Activation of mammalian target of rapamycin signaling pathway contributes to tumor cell survival in anaplastic lymphoma kinase-positive anaplastic large cell lymphoma.
Vega F; Medeiros LJ; Leventaki V; Atwell C; Cho-Vega JH; Tian L; Claret FX; Rassidakis GZ
Cancer Res; 2006 Jul; 66(13):6589-97. PubMed ID: 16818631
[TBL] [Abstract][Full Text] [Related]
25. CD31 expression in plasmacytic/plasmablastic lesions.
Plocharczyk E; Wakely PE
Ann Diagn Pathol; 2013 Dec; 17(6):498-501. PubMed ID: 24074836
[TBL] [Abstract][Full Text] [Related]
26. Overexpressed eIF4E is functionally active in surgical margins of head and neck cancer patients via activation of the Akt/mammalian target of rapamycin pathway.
Nathan CO; Amirghahari N; Abreo F; Rong X; Caldito G; Jones ML; Zhou H; Smith M; Kimberly D; Glass J
Clin Cancer Res; 2004 Sep; 10(17):5820-7. PubMed ID: 15355912
[TBL] [Abstract][Full Text] [Related]
27. Notch1 signaling pathway promotes invasion, self-renewal and growth of glioma initiating cells via modulating chemokine system CXCL12/CXCR4.
Yi L; Zhou X; Li T; Liu P; Hai L; Tong L; Ma H; Tao Z; Xie Y; Zhang C; Yu S; Yang X
J Exp Clin Cancer Res; 2019 Aug; 38(1):339. PubMed ID: 31382985
[TBL] [Abstract][Full Text] [Related]
28. [Study on activation of AKT/mTOR pathway in anaplastic large cell lymphoma].
Li JF; Li GD; Gu L; Liu WP; Li FY; Liao DY; Ma ZG
Zhonghua Xue Ye Xue Za Zhi; 2008 Oct; 29(10):649-53. PubMed ID: 19176054
[TBL] [Abstract][Full Text] [Related]
29. Orbital plasmablastic lymphoma--comparison of a newly reported entity with diffuse large B-cell lymphoma of the orbit.
Morley AM; Verity DH; Meligonis G; Rose GE
Orbit; 2009; 28(6):425-9. PubMed ID: 19929677
[TBL] [Abstract][Full Text] [Related]
30. Tissue inhibitor of metalloproteinase 1 (TIMP-1) promotes plasmablastic differentiation of a Burkitt lymphoma cell line: implications in the pathogenesis of plasmacytic/plasmablastic tumors.
Guedez L; Martinez A; Zhao S; Vivero A; Pittaluga S; Stetler-Stevenson M; Raffeld M; Stetler-Stevenson WG
Blood; 2005 Feb; 105(4):1660-8. PubMed ID: 15479729
[TBL] [Abstract][Full Text] [Related]
31. Imperatorin suppresses proliferation and angiogenesis of human colon cancer cell by targeting HIF-1α via the mTOR/p70S6K/4E-BP1 and MAPK pathways.
Mi C; Ma J; Wang KS; Zuo HX; Wang Z; Li MY; Piao LX; Xu GH; Li X; Quan ZS; Jin X
J Ethnopharmacol; 2017 May; 203():27-38. PubMed ID: 28341244
[TBL] [Abstract][Full Text] [Related]
32. Significance of 4E-binding protein 1 as a therapeutic target for invasive urothelial carcinoma of the bladder.
Nishikawa M; Miyake H; Behnsawy HM; Fujisawa M
Urol Oncol; 2015 Apr; 33(4):166.e9-15. PubMed ID: 25618298
[TBL] [Abstract][Full Text] [Related]
33. A clinical, molecular and cytogenetic study of 12 cases of human herpesvirus 8 associated primary effusion lymphoma in HIV-infected patients.
Boulanger E; Agbalika F; Maarek O; Daniel MT; Grollet L; Molina JM; Sigaux F; Oksenhendler E
Hematol J; 2001; 2(3):172-9. PubMed ID: 11920242
[TBL] [Abstract][Full Text] [Related]
34. Plasmablastic lymphoma versus plasmablastic myeloma: an ongoing diagnostic dilemma.
Ahn JS; Okal R; Vos JA; Smolkin M; Kanate AS; Rosado FG
J Clin Pathol; 2017 Sep; 70(9):775-780. PubMed ID: 28249941
[TBL] [Abstract][Full Text] [Related]
35. Vitamin D Receptor Expression in Plasmablastic Lymphoma and Myeloma Cells Confers Susceptibility to Vitamin D.
Gascoyne DM; Lyne L; Spearman H; Buffa FM; Soilleux EJ; Banham AH
Endocrinology; 2017 Mar; 158(3):503-515. PubMed ID: 28001444
[TBL] [Abstract][Full Text] [Related]
36. Cutaneous localization of plasmablastic multiple myeloma with heterotopic expression of CD3 and CD4: Skin involvement revealing systemic disease.
Varricchio S; Pagliuca F; Travaglino A; Gallo L; Villa MR; Mascolo M
J Cutan Pathol; 2019 Aug; 46(8):619-622. PubMed ID: 31025408
[TBL] [Abstract][Full Text] [Related]
37. Paradigm of kinase-driven pathway downstream of epidermal growth factor receptor/Akt in human lung carcinomas.
Dobashi Y; Suzuki S; Kimura M; Matsubara H; Tsubochi H; Imoto I; Ooi A
Hum Pathol; 2011 Feb; 42(2):214-26. PubMed ID: 21040950
[TBL] [Abstract][Full Text] [Related]
38. Diffuse large B-cell lymphomas with plasmablastic/plasmacytoid features are associated with TP53 deletions and poor clinical outcome.
Simonitsch-Klupp I; Hauser I; Ott G; Drach J; Ackermann J; Kaufmann J; Weltermann A; Greinix HT; Skrabs C; Dittrich C; Lutz D; Pötter R; Mannhalter C; Lechner K; Chott A; Jaeger U
Leukemia; 2004 Jan; 18(1):146-55. PubMed ID: 14603341
[TBL] [Abstract][Full Text] [Related]
39. Inhibition of mammalian target of rapamycin activates apoptosis signal-regulating kinase 1 signaling by suppressing protein phosphatase 5 activity.
Huang S; Shu L; Easton J; Harwood FC; Germain GS; Ichijo H; Houghton PJ
J Biol Chem; 2004 Aug; 279(35):36490-6. PubMed ID: 15218033
[TBL] [Abstract][Full Text] [Related]
40. Enhanced sensitivity of multiple myeloma cells containing PTEN mutations to CCI-779.
Shi Y; Gera J; Hu L; Hsu JH; Bookstein R; Li W; Lichtenstein A
Cancer Res; 2002 Sep; 62(17):5027-34. PubMed ID: 12208757
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]